| abstract |
In the treatment or prevention of anemia secondary to or associated with chronic kidney disease, anemia secondary to or associated with non-dialysis-dependent chronic kidney disease, anemia associated with or resulting from chemotherapy, or anemia associated with AIDS Specific dosages for use of HIF prolyl hydroxylase inhibitors, and dosing regimens for use are provided herein. [Selection] Figure 1A |